Skip to main content
Log in

Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Ten patients with Alzheimer's disease were treated with intravenous infusion of physostigmine for 2 h. The acute effects on cognitive function, regional cerebral blood flow, and EEG were compared to placebo (isotonic glucose) using a double-blind cross-over design. Physostigmine causes a limited improvement of psychomotor performance and EEG and an increase of blood flow in the most severely affected cortical areas, predominantly in an early phase of Alzheimer's disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bowen DM, Smith CB, White P, Davison AN (1976) Neurotrans-mitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophics. Brain 99:459–496

    PubMed  CAS  Google Scholar 

  • Bowen DM, Spillane JA, Curzon G, Meier-Ruge W, White P, Goodhardt MJ, Iwangoff P, Davison AN (1979) Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet II:11–14

    Google Scholar 

  • Brun A, Gustafson L (1976) Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Arch Psychiatr Nervenkr 223:15–33

    Article  PubMed  CAS  Google Scholar 

  • Brun A, Gustafson L (1978) Limbic lobe involvement in presenile dementia. Arch Psychiatr Nervenkr 226:79–93

    Article  PubMed  CAS  Google Scholar 

  • Brun A, Englund E (1981) Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 5:549–564

    PubMed  CAS  Google Scholar 

  • Catagirone C, Gainotti G, Masullo C (1982) Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 16:247–249

    Google Scholar 

  • Caltagirone C, Albanese A, Gainotti G, Masullo C (1983) Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 18:143–148

    PubMed  CAS  Google Scholar 

  • Christie JE, Shering A, Ferguson J, Glen AIM (1981) Physostigmine and arecholine: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50

    Article  PubMed  CAS  Google Scholar 

  • Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1403

  • Davies P, Verth AH (1978) Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res 138:385–392

    Article  Google Scholar 

  • Davis KL, Mohs RC (1982) Enhancment of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139(11):1421–1424

    PubMed  CAS  Google Scholar 

  • Frackowiak RSJ, Pozzilli C, Legg NJ, du Boulay GH, Marschall J, Lenzi GL, Jones T (1981) Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with oxygen-15 and positron tomography. Brain 104:753–778

    PubMed  CAS  Google Scholar 

  • Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE (1983) Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with (18F) fluorodeoxyglucose. J Comput Assist Tomogr 7(4):590–598

    PubMed  CAS  Google Scholar 

  • Gustafson L, Risberg J (1979) Regional cerebral blood flow measurements by the 133-Xe inhalation technique in differential diagnosis of dementia. Acta Neurol Scand [Suppl 72] 60:546–547

    Google Scholar 

  • Gustafson L, Nilsson L (1982) Differential diagnosis of presenile dementia on clinical grounds. Acta Psychiatr Scand 65:194–209

    PubMed  CAS  Google Scholar 

  • Gustafson L, Risberg J, Johanson M, Brun A (1984) Evaluation of organic dementia by regional cerebral blood flow measurements and clinical and psychometric methods. Monogr Neural Sci 11:111–11

    PubMed  CAS  Google Scholar 

  • Hachinski VC, Iliff LD, Zilhka E, du Boulay GH, McAllister VL, Marshall J, Ross Russel RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637

    PubMed  CAS  Google Scholar 

  • Hagberg B (1979) Comments on physostigmine assessment in dementia with early onset with special reference to Alzheimer's disease. Presented at Colloquium on Alzheimer's disease. Early recognition of potentially reversible deficits. Edinburgh

  • Hagberg B, Ingvar DH (1976) Cognitive reduction in presenile dementia related to regional abnormalities of the cerebral blood flow. Br J Psychiatry 128:209–222

    Article  PubMed  CAS  Google Scholar 

  • Karczmar AG (1977) Exploitable aspects of central cholinergic functions particularly with respect to the EEG, motor, analgetic, and mental functions. In: Jenden D (ed) Cholinergic mechanisms and psychopharmacology. Plenum, New York, pp 679–708

    Google Scholar 

  • Kuhl DE, Metter EJ, Riege WH, Hawkins RA, Mazziotta JC, Phelps ME, Kling AS (1983) Local cerebral glucose utilization in elderly patients with depression, multiple infarct dementia, and Alzheimer's disease. J Cereb Blood Flow Metab 3 [Suppl 1] 3:494–495

    Google Scholar 

  • Muramoto O, Sugishita M, Ando K (1984) Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 47:485–491

    PubMed  CAS  Google Scholar 

  • Obrist WD, Thompson HK, Wang HS, Wilkinson WE (1975) Regional cerebral blood flow estimated by 133-xenon inhalation. Stroke 6:245–256

    PubMed  CAS  Google Scholar 

  • Perry EK (1986) The cholinergic system in old age and Alzheimer's disease. Age Ageing 9:1–8

    Google Scholar 

  • Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 189

  • Pfefferbaum A, Davis KL, Coulter CL, Mohs RC, Tinklenberg JR, Kopell BS (1979) EEG effect of physostigmine and choline chloride in humans. Psychopharmacologia 62:225–233

    Article  CAS  Google Scholar 

  • Risberg J (1980) Regional cerebral blood flow measurements by 133-Xe inhalation: Methodology and applications in neuropsychology and psychiatry. Brain Lang 9:9–34

    Article  PubMed  CAS  Google Scholar 

  • Rossor MN, Svendsen C, Hunt SP, Mountjoy CQ, Roth M, Iversen LL (1982) The substantia innominata in Alzheimer's disease: A histochemical and biochemical study of cholinergic marker enzymes. Neurosci Lett 28:217–222

    Article  PubMed  CAS  Google Scholar 

  • Sitaram M, Wyatt RJ, Dawson S, Gillin JC (1976) REM sleep induction by physostigmine during sleep. Science 191:1281–1282

    PubMed  CAS  Google Scholar 

  • Thal LJ, Fuld PA, Masur DM, Sharpless NS (1983) Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 13:491–496

    Article  PubMed  CAS  Google Scholar 

  • White P, Goodhardt MJ, Keet JK, Hiley CR, Carrasio LH, Williams IEI (1977) Neocortical cholinergic neurons in elderly people. Lancet 668–671

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gustafson, L., Edvinsson, L., Dahlgren, N. et al. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 93, 31–35 (1987). https://doi.org/10.1007/BF02439583

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02439583

Key words

Navigation